MedDataX Logo

Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease

NCT ID: NCT00184652

Last Updated: 2017-01-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-04-30

Study Completion Date

2005-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial is conducted in Asia, Europe, and Middle East. Adult patients with chronic kidney disease are treated with growth hormone to assess effect on nutritional status.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Growth Hormone on Bone Mineral Density in Young Adults With Child-hood Onset Growth Hormone Deficiency

NCT00184678

Growth Hormone Disorder Adult Growth Hormone Deficiency
COMPLETED PHASE3

The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis

NCT00503698

Chronic Kidney Disease End-Stage Renal Disease
TERMINATED PHASE3

Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients

NCT01562834

Growth Hormone Disorder Adult Growth Hormone Deficiency
COMPLETED PHASE4

Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083

NCT00715689

Growth Hormone Disorder Adult Growth Hormone Deficiency
COMPLETED PHASE2

Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.

NCT00184769

Chronic Kidney Disease Chronic Renal Insufficiency
COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Disease End-Stage Renal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

somatropin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ESRD patients

Exclusion Criteria

* Diabetes Mellitus
* Severe and Malignant diseases
* Patients in Intensive Care Units
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novo Nordisk A/S

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Global Clinical Registry (GCR 1452)

Role: STUDY_DIRECTOR

Novo Nordisk A/S

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Novo Nordisk Investigational Site

Århus N, , Denmark

Site Status

Novo Nordisk Investigational Site

København Ø, , Denmark

Site Status

Novo Nordisk Investigational Site

Odense, , Denmark

Site Status

Novo Nordisk Investigational Site

Berlin, , Germany

Site Status

Novo Nordisk Investigational Site

Heidelberg, , Germany

Site Status

Novo Nordisk Investigational Site

Hong Kong, , Hong Kong

Site Status

Novo Nordisk Investigational Site

Holon, , Israel

Site Status

Novo Nordisk Investigational Site

Kfar Saba, , Israel

Site Status

Novo Nordisk Investigational Site

Petah Tikva, , Israel

Site Status

Novo Nordisk Investigational Site

Ramat Gan, , Israel

Site Status

Novo Nordisk Investigational Site

Tel Aviv, , Israel

Site Status

Novo Nordisk Investigational Site

Tzriffin, , Israel

Site Status

Novo Nordisk Investigational Site

Krakow, , Poland

Site Status

Novo Nordisk Investigational Site

Lublin, , Poland

Site Status

Novo Nordisk Investigational Site

Wołomin, , Poland

Site Status

Novo Nordisk Investigational Site

Singapore, , Singapore

Site Status

Novo Nordisk Investigational Site

Gothenburg, , Sweden

Site Status

Novo Nordisk Investigational Site

Bern, , Switzerland

Site Status

Novo Nordisk Investigational Site

Birmingham, , United Kingdom

Site Status

Novo Nordisk Investigational Site

Coventry, , United Kingdom

Site Status

Novo Nordisk Investigational Site

Glasgow, , United Kingdom

Site Status

Novo Nordisk Investigational Site

Liverpool, , United Kingdom

Site Status

Novo Nordisk Investigational Site

Manchester, , United Kingdom

Site Status

Novo Nordisk Investigational Site

Newcastle, , United Kingdom

Site Status

Novo Nordisk Investigational Site

Sheffield, , United Kingdom

Site Status

Novo Nordisk Investigational Site

Swansea, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark Germany Hong Kong Israel Poland Singapore Sweden Switzerland United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Feldt-Rasmussen B, Lange M, Sulowicz W, Gafter U, Lai KN, Wiedemann J, Christiansen JS, El Nahas M; APCD Study Group. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol. 2007 Jul;18(7):2161-71. doi: 10.1681/ASN.2006111207. Epub 2007 Jun 6.

Reference Type RESULT
PMID: 17554147 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://novonordisk-trials.com

Clinical Trials at Novo Nordisk

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NN1606-1442

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Observational Prospective Study on Patients Treated With Norditropin®
NCT00960128 COMPLETED
Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function
NCT03186495 COMPLETED PHASE1
Safety and Efficacy of Long-term Somatropin Treatment in Adults
NCT01543880 COMPLETED
Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency
NCT01698944 TERMINATED PHASE4
A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency
NCT01706783 COMPLETED PHASE1
Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)
NCT00184730 COMPLETED PHASE3
Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone Deficiency
NCT01109017 COMPLETED
Effect of Growth Hormone in Children With Growth Hormone Deficiency
NCT00262249 COMPLETED PHASE3
Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children
NCT00102817 COMPLETED PHASE3
Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency
NCT01502124 COMPLETED PHASE3
A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood
NCT00212758 COMPLETED PHASE4
Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers
NCT01401244 COMPLETED PHASE1
Growth Hormone Treatment of Children Diagnosed of Intrauterine Growth Retardation
NCT01697644 COMPLETED PHASE4
Long Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation
NCT01734447 COMPLETED PHASE4
Bioequivalence of Two Products (Norditropin® Versus Nutropin AQ®) in Healthy Adult Volunteers
NCT01512095 WITHDRAWN PHASE1
A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency
NCT02382939 COMPLETED PHASE3
National Cooperative Growth Study in CKD
NCT00616278 COMPLETED
Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth Hormone
NCT01327924 COMPLETED
Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.
NCT02229851 COMPLETED PHASE3
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
NCT02558829 COMPLETED PHASE3
Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome
NCT01529840 COMPLETED PHASE3
Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects
NCT01343641 WITHDRAWN PHASE2
Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients
NCT00570011 COMPLETED PHASE3
GH and Cardiovascular Risk Factors
NCT01877512 COMPLETED PHASE4
Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)
NCT00184743 COMPLETED PHASE3